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Introduction
Alzheimer’s Disease (AD) is the most common form of 
dementia in the elderly (50-60% of all dementia)1 and is one 
of the major causes of disability in today’s population. Only 
in Europe 10 million2 people suffer from dementia while 
the world figure is approximatelly 20-30 million1. It is pre-
dicted that worldwide prevalence will drastically increase 
due to an increasing number of elderly in the population3. 
Unfortunatelly, current pharmacotherapy  does not 
provide satisfactory  support to AD patients1 since all 
available  drugs for AD are symptomatic, reducing the 
extent of cognitive decline in less than 30% of all AD sub-
jects, and typically for only 6-12 months4,5. 
The management of AD has few important  goals which 
include: (1) early diagnosis; (2) optimizing physical health, 
cognitive status, activity and quality of life; (3) observing 
and treating psychological symptoms and symptoms of 
behavior; and (4) providing information and long-term 
support to caregivers / families6.
AD is undoubtedly accepted as a complex disease of 
multiple factors due to the presence of numerous interre-
lated genetic factors and environmental factors7. Basi-
cally, risk factors can be divided into two groups: (1) those 
that can not be modified (age, family history of the dis-
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ease); and (2) the ones that can be modified8. Risk factors 
that can be modified amongst others include also those 
that are directly related to the way of life - nutrition, edu-
cation, physical activity, smoking, alcohol consumption 
and social relations9.
Over the past few years, there is growing evidence that 
nutrition, one of the most important factors of quality of 
life that we can change, plays a significant role in prevent-
ing and / or cessation of cognitive decline and AD that 
today present one of the major public health issues10. Re-
search has shown that the relationship between diet and 
AD is similar to that of diet and cardiovascular disease(s)11, 
but there are still no nutrition guidelines for treatment of 
AD although we have promising results of isolated food 
components such as certain vitamins, energy substrates, 
flavonoids and lipids12. Therefore  there are increasingly 
apparent aspirations for dietetics research on AD that will 
focus not only on isolated components of food but on food 
as a whole which is present in the ordinary diet of an in-
dividual13.
Apples and apple products
Numerous studies have shown association between the 
consumption of fruits and vegetables and improved health, 
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especially for the consumption of biologically active sub-
stances or phytochemicals from foods of plant origin that 
play a major role in the modulation of numerous processes 
in the body responsible for the development of the disease, 
including AD14. 
The greatest attention is given to flavonoids which are 
considered responsible for the positive effects of certain 
foods of plant origin on health in general. The most com-
mon flavonoids in fruit and vegetables are quercetin and 
its conjugates15.
Since they are one of the first three (3) dietary sources 
of polyphenols in humans and are available throughout 
the year it is clear that apples and apple products are one 
of the main foods for assessing their effects on human 
TABLE 1
A REVIEW OF SCIENTIFIC RESEARCH ON THE EFFECT ON CONSUMATION OF APPLE AND ITS PRODUCTS AND/OR 
BIOACTIVE COMPONENTS ON THE DELAY OF ONSET, PREVENTION AND/OR THERAPY OF CHRONIC DISEASES
Author Year Indication Materials and 
methods
Subjects Result





21% reduced risk in women
27Le Marchand  et al. 2000 Lung cancer Consumation of 
apples and onions
Reduced risk in women and men
28Knekt  et al. 2002 Lung cancer flavonoids 10,00 men and 
women in Finland
Reduced risk
29Arts  et al. 2000 Epithelial lung caner apples 728 men Reduced incidence
30Sesso  et al. 2003 Cardiovascular diseases flavonoids 40,000 women 35% reduced risk of cardiovascular 
disease
32Knekt  et al. 2000 Thrombotic effects apples Population in 
Finland
Reduced risk
32Knekt  et al. 1996 Coronary mortality flavonoids Population in 
Finland
Reduced risk in women but not in 
men
29Arts  et al. 2001 Coronary heart disase Apples and wine 35,000 women in 
Iowa
Reduced risk from coronary heart 
disease
33Woods  et al. 2003 Asthma Apples and pears 1,600 people in 
Australia
Reduced risk from asthma and 
bronchial sensitivity
34Shaheen  et al. 2001 Asthma Apples and selenium 600  people in Great 
Britain
Reduced risk
28Knekt  et al. 2002 Asthma
Diabetes mellitus type II




35Tabak  et al. 2001 Lung function Apples 13,000 people in 
Netherlands
Possible positive correlation in lung 
function reduced risk from chronic 
opstructive lung disease
36Butland  et al. 2000 Lung function apples 2,500 men in Wales Positive correlation
37de Oliviera  et al. 2003 Decrease of body mass 
Decrease of blood glucose




38Ravn-Haren  et al. 2013 Decrease of plasma lipids Whole apples and 
apple juice
Positive correlation
39Brouns  et al. 2012 Hipercholesterolemia Pectin from apples Men and women with 
high cholesterol
Reduced levels of cholesterol
40Sanchez et al. 2008 Insulin resistance Pectin from apples mice Improvement of glucose metabolism
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health14. In the United States (USA), 22% of total input of 
fruit phenols comes from apples; in Finland apples and 
onions are the main sources of flavonoids from food; and 
in the Netherlands apples are in third place of total flavo-
noid intake from food, behind tea and onions16.
Apple (Malus domestica) belongs to the Rosaceae fam-
ily which also includes apricots, spinach, peaches, pears 
and plums. The annual world apple production in 
2011/2012 was estimated at 65.23 million square tons, of 
which 12.2 million square tons were used to produce apple 
juice17.
When looking at the total concentration of phenolic 
compounds, apples are in second place, immediately be-
hind cranberries. What is more important is that apples 
have the highest amount of free phenolic compounds com-
pared to other fruits, meaning that phenolic compounds 
are not related to other fruit components and thus are 
bioavailable in the human organism after consumption18.
Numerous studies have been conducted on the poten-
tial beneficial effect of apples on human health as well as 
on the reduction of the risk of chronic illness and as chron-
ic disease therapy (Table 1).
Apple compounds
Apples have low fat content and a high proportion of 
carbohydrates where fructose is dominant. They are also 
excellent sources of vitamins (especially vitamin C), min-
erals (potassium and magnesium), triterpenoids (ursolic 
acid), dietary fiber (soluble and insoluble) and polyphe-
nols19.
Apples contain about 2–3% dietary fiber20. They are 
rich in insoluble fiber including cellulose and hemicellu-
lose. From soluble fiber, apples contain pectin - one of the 
most soluble apple fibers, homogalacturonans and ramno-
galacturonans. It is considered that apple pectin has the 
properties of lowering cholesterol21 as well as positive ef-
fects on glucose metabolism22.
One of the important quality features of apples is the 
amount of polyphenols. Five major polyphenolic groups are 
found in apples: flavanols, phenolic acids, flavonols, dihy-
drochalcones and anthocyanins23. Polyphenols are studied 
intensively due to many positive effects like their antican-
cerogenic24 and antiviral properties2
Apples contain a significant amount of phytochemicals 
especially flavonoids whose concentration is conditioned 
by numerous factors - cultivation, harvesting, storage and 
processing of raw materials. The type and concentration 
of flavonoids are also different depending on whether they 
are in the apple bark or core. The most prominent apple 
flavonoids are quercetin-3-galactoside, quercetin-3-gluco-
side, quercetin-3-ramnoside, catechin, epicatechin, procy-
anidin, cyanidin-3-galactoside, coumaric acid, chlorogen-
ic acid, gallic acid and florizin16.
In the apple bark we usually find procyanidines, cat-
echins, epicatechins, chlorogenic acid, florizine and quer-
cetin conjugates. In the apple core the following fitonutri-
ents are present: catechol, epicatechin, procyanidine and 
florizine but at a significantly lower concentration than in 
the apple bark. The quercetin conjugates are therefore 
found only in the bark and the only flavonoid which is 
found in higher concentration in the apple core in relation 
to the bark is chlorogenic acid41.
In addition to the part of the apple the flavonoid content 
is also affected by the ripening of the fruit itself. Concen-
trations of quercetine, florizine and catechin glycosides as 
well as  chlorogenic acid are higher at the beginning of the 
apple season and decrease with fruit ripening42.
Apples that have higher exposure to sunlight have 
more flavonoids43.
Studies have also shown that storage under controlled 
atmospheric conditions over a year does not significantly 
affect the concentration of flavonoids in apples44.
Potentially beneficial effects of apples on 
health 
For apples, especially apple bark, strong antioxidant 
properties have been proven. The total antioxidant activ-
ity of apple with the bark was approximately 83 μmol 
equivalent of vitamin C (total antioxidant activity of 100g 
apple is about 1500mg equivalent of vitamin C), although 
the content of vitamin C in 100g apples is approximately 
5.7 mg45. Thus it is evident that although vitamin C is a 
strong antioxidant, almost all antioxidant activity of ap-
ples is a result from other compounds while vitamin C 
antioxidant activity accounts for only 0.6%.4
In addition to antioxidant capacity apples also exhibit 
an antiproliferative effect as they inhibit cell proliferation, 
probably due to a unique combination of phytochemicals45, 
and compared to 11 other frequently consumed fruit foods, 
are third in antiproliferative activity47.
Inhibition of lipid peroxidation has been demonstrated 
for apple phenols in human serum, which is the strongest 
3 hours after consumation and initial serum levels are 
restored after 24 hours48. The same has been confirmed 
after consumption of apple juice in mice, where reduced 
levels of malonaldehyde (MDA), a lipid peroxidation bio-
marker, have been demonstrated49. 
One of the main apple flavonoids – quercetin, when 
isolated did not have any effect on lipid peroxidation in 
mice suggesting that apple properties in reducing lipid 
peroxidation are the result of a combination of phytonutri-
ents in the apple itself49.
Along with the effect on lipid peroxidation, it has been 
found in humans that after consumption of apple juice 
there is an increase in glutathione peroxidase levels - bio-
markers of oxidative stress49.
Apples and apple products also show a strong influence 
on preventing the risk of developing cardiovascular 
disease(s) due to their ability to reduce cholesterol levels 
attributable to the combined action of polyphenolic compo-
nents and apple nutritional fibers49.
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pared to fruit suggesting that fruit juices are comparable 
to sugar-sweetened beverages has been denied when evi-
dence published in 2006 suggested that the 100% fruit 
juices (with no added nonjuice components, sweeteners 
etc.) retain the majority of nutrients and phytochemicals 
of whole fruit and therefore show potential benefit on hu-
man health59. 
With the exception of fiber and vitamin C, one small 
fruit or half a cup of fruit is similar in vitamin and min-
eral content to one half of a cup of 100% fruit juice61.
Fruit and vegetable juices may play an important role 
in delaying the onset of Alzheimer’s disease, particularly 
among those who are at high risk for the disease. These 
results may lead to a new avenue of inquiry in the preven-
tion of Alzheimer’s disease62.
As different polyphenol forms have been studied for 
cognitive benefits in the elderly, it has been demonstrated 
that apple, grape and wine extracts rich in antocyanins 
and flavan-3-ols show the ability to minimize cognitive 
decline in rodent models of AD.2 Interventional studies in 
people older than 45 years with mild cognitive decline 
display potential improvement in several assessment 
tools, in particular verbal memory and word recognition64.
It has been shown that regular consumption of fresh 
apples increases the level of antioxidative enzymes in 
erythrocytes of the elderly and thus raises total antioxida-
tive potential of the organism65. An antioxidant effect can 
be registered as soon as 30 minutes after consuming 150 
ml of apple juice and is present for about 60 minutes66. 
Although 43 apple juice components have been isolated, it 
is not quite clear which of them attribute to the antioxi-
dant effect the most since all of them exhibit an antioxi-
dant effect at some level67. Quercetin and floretine seem 
to be the most effective68. 
Quercetin has also shown decreases in extracellular 
β-amyloidosis, tauopathy, astrogliosis and microgliosis in 
the hippocampus and the amygdala and has induced im-
proved performance on learning and spatial memory tasks 
and greater risk assessment behaviour based on the ele-
vated plus maze test70. 
In all likelihood, the antioxidative potential of apple 
juice is responsible for the repairment of behavioral disor-
ders and learning abilities on animal models with 
AD71,72,73, while the same model shows regenerative effects 
of apple juice on damaged synapses74 whose damage is 
considered the key to functional neuropathology of AD. 
Apple juice concentrate, administered ad libitum in 
drinking water has been found to compensate for the in-
creased reactive oxygen species and decline in cognitive 
performance in maze trials observed when normal and 
transgenic mice lacking apolipoprotein E are deprived of 
folate and vitamin E71. 
Supplementation with apple juice concentrate also pre-
vents the increases in glutathione synthase transcription 
and activity which provides further evidence that the an-
tioxidant potential of apple juice concentrate can compen-
sate for dietary and genetic deficiencies that otherwise 
promote neurodegeneration72,75.
Effect of apple and apple products on AD
Evidence suggests that reactive oxygen species in brain 
may play a role in the development of age-related neuronal 
impairments. The increase in the concentration of the pro-
infl ammatory cytokines in aged brain tissue may also 
represent a contributory factor50.
Previous studies on the effect of apples and apple prod-
ucts (ex. juice, concentrate etc.) on oxidative processes and 
symptoms of AD, primarily due to its high phytochemicals 
content14,51, are very good scientific bases for future con-
trolled clinical trials. One of the most important factors 
involved in age-related cognitive decline is the accumula-
tion and constant repeated exposure to reactive oxygen 
species (ROS) which leads to a reduction of the ability to 
mitigate long-term effects of oxidative stress52. Oxidative 
stress has been shown in numerous studies to precede the 
cardinal neuropathologic manifestations of AD and oxida-
tive modifications are further seen in cerebral tissue in 
early stages of AD. Oxidation of nucleic acids, proteins and 
lipids are prominent and early changes in AD53. 
Antioxidant therapy is therefore one of the promising 
theraputic strategies for AD54. Daily consumption of a bev-
erage with high antioxidant power, combining extracts of 
green tea and apple over a period of 8 months in 100 pa-
tients (48 AD patients and 52 controls) has shown preven-
tion of decrease of antioxidant status and increase in an-
tioxidant enzymes values in patients with AD55. 
A vitamin/nutraceutical formulation containing folate, 
vitamin 12, alpha-tocopherol, S-adenosyl methionine, N-
acetyl cysteine and acetyl-L-carnitine (of which all are 
nutrients found in apples) showed a clinically significant 
delay in decline in the Dementia Rating Scale and clock-
drawing test in patients with AD compared to the placebo 
group after 9 months of consumation56. 
A formulation of folate, vitamin 6, alpha-tocopherol, 
S-adenosyl methionine, N-acetyl cysteine and acetyl-L-
carnitine in a 12-month, open-label trial with 14 commu-
nity-dwelling individuals with early-stage Alzheimer’s 
disease showed improvement in the Dementia Rating 
Scale and Clock-drawing tests. Family caregivers also 
reported improvement in multiple domains of the Neuro-
psychiatric Inventory (NPI) where the Performance on the 
NPI was equivalent to published findings at 3 to 6 months 
for donepezil and exceeded that of galantamine and their 
historical placebos57.
On the other hand, a double-blind, multi-site, phase II 
study was conducted in which 106 individuals with AD 
were randomized to a nutraceutical formulation (NF; fo-
late, alpha-tocopherol, B12, S-adenosyl methioinine, N-
acetyl cysteine, acetyl-L-carnitine) or placebo for 3 or 6 
months, followed by an open-label extension where par-
ticipants received NF for 6 additional months. Results 
showed that the NF cohort improved versus the placebo 
cohort within 3 months58. 
Although it is universally accepted that fruit and veg-
etables intake is protective, there is no clear consensus 
about the effects of consuming the juices that are extract-
ed from them59,60. Concerns about the lower fiber content 
and the higher caloric density of fruit juices when com-
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 Apple juice concentrate administered in drinking wa-
ter maintains acetylcholine levels that otherwise decline 
when adult and aged mice are maintained on a diet defi-
cient in folate and vitamin E and containing iron as a 
pro-oxidant which shows that the consumption of antiox-
idant-rich foods such as apples can prevent the decline in 
cognitive performance that accompanies dietary and ge-
netic deficiencies and aging76.
 It also appears that apple juice reduces the expression 
of presenilin-173, proteins responsible for the deposition of 
insoluble β-amyloid, whose brain accumulation is patho-
gnomic to AD. Apolipoprotein E function increases the 
oxidative stress and potentiates the deleterious activity of 
preseniline-1 as well as folate deficiency increases prese-
niline-1 expression, a study was conducted to review the 
effect of apple juice concentrate on presenilin-1 expression 
in ApoE deficient mice. Study results showed that apple 
juice concentrate prevented or decreased these increases77. 
S-adenosylmethionine (SAM) is another compound 
that is easily depleted due to lack of folate and also leads 
to preseniline-1 overexpression thus neurodegeneration. 
Direct supplementation of SAM has shown to attenuate 
preseniline-1 overexpression and since apple juice concen-
trate contains levels of SAM that are sufficient to prevent 
preseniline-1 overexpression, more evidence is available 
that apple juice concentrate is beneficial in prevention of 
cognitive decline77.
Since a portion of neurotoxicity of amyloid-beta is due 
to oxidative stress, a study was conducted to review the 
effect of apple juice on amyloid-beta in patients with AD 
through an apple juice concentrate. Apple juice concen-
trate prevented the increased generation of reactive oxy-
gen species (ROS) normally induced by amyloid-beta treat-
ment under these conditions and it also prevented 
amyloid-beta-induced calcium influx and apoptosis, each 
of which results in part due to increased ROS. These find-
ings suggest that the antioxidant potential of apple prod-
ucts can prevent amyloid-beta-induced oxidative damage78.
It has been shown that apple juice concentrate dose not 
alter overall signaling, but fosters an organization of sig-
nals into less frequent and longer »bursts« of activity. It 
seems that apple juice concentrate modulates signaling 
patterns by stimulating the activity of inhibitory neurons 
which shows that apple juice concentrate may foster im-
proved cognition at least in part by stimulation of inhibi-
tory activity in situ79. 
Aged rats fed with a diet enriched with fresh apples 
showed a significant decrease in anxiety levels and they 
improved their ability to sustain long-term potentiation 
(LTP) by reaching the level of young rats. Furthermore, 
superoxide dismutase (SOD) activity was increased in 
aged rats who were fed with a standard diet, while the 
SOD activity of aged rats fed with the fresh apple-enriched 
diets was at a level of young animals74.Apple juice also 
reduces the neurotoxicity of soluble β-amyloid oligomers 
in vitro, which is attributed to the effect of S-adenosyl 
methionine (SAM) in apple juice80. SAM can exert a direct 
effect on glutathione S-transferase (GST) activity. AD is 
accompanied by reduced GST activity, diminished SAM, 
and increased S-adenosylhomocysteine (SAH), the down-
stream metabolic product resulting from SAM-mediated 
transmethylation reactions, when deprived of folate. Due 
to this, it is believed that SAM plays a critical role in 
maintenance of neuronal health and suggesting a possible 
role of SAM as a neuroprotective dietary supplement for 
AD patients81.
Caffeic acid which is also one of the nutrients found in 
apple juice has shown beneficial effects on learning ability 
in rat models with AD where caffeic acid significantly re-
duced learning deficits and increased cognitive function in 
the rats with AD. Caffeic acid administration also resulted 
in a significant decrease in acetylcholinesterase activity 
and nitrite generation and suppressed oxidative stress, in-
flammation, nuclear factor-κB-p65 protein expression and 
caspase-3 activity as well as regulating the protein expres-
sion of p53 and phosphorylated (p-)p38 MAPK expression 
in the rats with AD. Thus it seems that the beneficial ef-
fects of caffeic acid on learning deficits in a model of AD 
were due to the suppression of oxidative stress and inflam-
mation through the p38 MAPK signaling pathway82.
A study that reviewed protective effects of coffee com-
ponents determined that quercetin reduced oxidative/ni-
trative damage to DNA, as well as to the lipids and pro-
teins of SH-SY5Y cells. There was also a resultant 
increase in GSH, an antioxidant enzyme, in SH-SY5Y 
cells which all indicates that quercetin, which is also a 
major component in apples, is the major neuroprotective 
component in coffee against Parkinson’s disease and Al-
zheimer’s disease82.
Conclusion
Numerous epidemiologic studies have shown the poten-
tial benefit of apples and their products on various chron-
ic diseases including neurodegenerative diseases such as 
AD. In vitro and animal studies have demonstrated that 
apples, apple juices and apple juice concentrates have high 
antioxidant activity and therefore the ability to alter neu-
rodegenerative processes in AD brains. 
Although the isolated compounds and phytonutrients 
in apples such as quercetine each for themselves show sig-
nificant antioxidant and protective activity, it seems that 
the combination of phytonutrients in apples is responsible 
for the beneficial effects on neurodegeneration.
Through different in vitro, animal and human studies, 
apples and their products have shown numerous different 
effects on AD clinical signs and symptoms thus showing 
their potential benefit and supportive use in the treatment 
of AD for which the requirement of randomized clinical 
trials is necessary in the future. 
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UTJECAJ JABUKE I NJEZINIH PROIZVODA NA NEURODEGENERACIJU I ALZHEIMEROVU 
BOLEST
S A Ž E T A K
Neurodegenerativni poremećaji kao što je Alzheimerova bolest (AB) opasni su po život i veliki ekonomski teret zdravst-
venom sustavu. Sadašnja farmakoterapija AB je simptomatska i usredotočena gotovo isključivo na bihevioralne smet-
nje dok puno simptoma nije liječeno osobito u području promjena raspoloženja i simptoma ponašanja. Stoga se pokazala 
potreba za potpornom terapijom i nutritivnom podrškom u obliku nutraceutika i kompleksnih namirnica, te su prove-
dena brojna istraživanja s ciljem utvrđivanja idealnog prehrambenog kompleksa i složene hrane za podršku u liječenju 
AB. Budući da je oksidativni stres u mozgu glavni simptom AB, hrana bogata antioksidantima identificirana je kao 
potencijalni nutraceutik za AB. Zbog sadržaja hranjivih tvari i njihovog antioksidacijskog učinka, čini se da jabuka 
predstavlja jednu od najboljih složenih namirnica u nutritivnoj potpori AB. U ovom članku ćemo prikazati pregled 
istraživanja koji pokazuju potencijalnu dobrobit jabuka na ljudsko zdravlje, kombinaciju spojeva jabuka i njihov zaštitni 
učinak na neurodegeneraciju i AB.
